Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Star Bulk Carriers Corp. Announces That It Has Become a Signatory of the “Neptune Declaration .
Star Bulk Carriers Corp.January 28, 2021 GMT
ATHENS, Greece, Jan. 28, 2021 (GLOBE NEWSWIRE) Star Bulk Carriers Corp. (the “Company” or “Star Bulk”) (Nasdaq: SBLK), a global shipping company focusing on the transportation of dry bulk cargoes, announced today that it has become a signatory of the “Neptune Declaration on Seafarer Wellbeing and Crew Change”, a worldwide call to action to end the unprecedented crew change crisis caused by the Covid-19 pandemic.
DBV Technologies S.A.: Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today issued the Half-Year report on its liquidity contract with ODDO BHF.
As of December 31, 2020, the following assets appeared on the liquidity account:
112,302 DBV Technologies shares;
€ 229,086.53.
24,313 DBV Technologies ordinary shares;
€ 682,454.94.
Purchase: 1,180
517,291 DBV Technologies ordinary shares purchased for €2,005,858.40
458,090 DBV Technologies ordinary shares sold for €1,841,496.60
About DBV Technologies
DBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBV s method of delivering biologically active co
Ortho Clinical Diagnostics Announces Pricing of Initial Public Offering
News provided by
Share this article
Share this article
RARITAN, N.J., Jan. 27, 2021 /PRNewswire/ Ortho Clinical Diagnostics Holdings plc ( Ortho ), the world s largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the pricing of its initial public offering of 76 million ordinary shares at $17.00 per share. The gross proceeds raised from this offering are expected to be $1,292 million. Ortho s ordinary shares are expected to begin trading on The Nasdaq Global Select Market on January 28, 2021, under the symbol OCDX, and the offering is expected to close on February 1, 2021, subject to customary closing conditions.